期刊文献+

Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis 被引量:4

Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis
下载PDF
导出
摘要 BACKGROUND: Although resection is the major treatment for patients with hepatocellular carcinoma ( HCC), the high intrahepatic recurrence remains a cardinal cause of death. This study was undertaken to evaluate the effect of hepatic arterial infusion chemotherapy on the survival and recurrence of HCC patients with hepatitis B virus ( HBV) cirrhosis after resection. METHODS: Twenty-eight patients who had undergone placement of a hepatic arterial pump at the time of liver wedge resection for HCC from 1998 through 2004 were reviewed retrospectively. These patients aged 23-71 years had HBV cirrhosis (Child-Pugh class A or B). They were given floxuridine(FUDR) (250 mg), doxorubicin (10 mg) and mitomycin C (4 mg) alternatively every 2 or 3 days through arterial pumps for 8 cycles each year in the first two years after resection. Meanwhile, traditional Chinese herbal medicine was prescribed to the patients. When the leucocyte count was as low as 3 x 109/L or asparate aminotransferase (AST) level was significantly increased, the regimen of chemotherapy was delayed for the normalization of leucocyte count and AST level (below 80 U/L). RESULTS: Of the 28 patients, 23 received 8 or 16 cycles of the set regimen of chemotherapy. These patients are alive with no evidence of recurrence. Among them, 5,7, and 11 patients are alive beyond 5 years, 3 years, and 1 year respectively. In the remaining 5 patients, 3 who had had a HCC 10 cm or more in diameter showed tumor recurrence within 1 year, in whom, 8 cycles of chemotherapy were not completed because of their low leucocyte count (<3 × 109/L) and poor liver function. One patient who had received 8 cycles of chemotherapy demonstrated recurrence at 16 months after resection. One patient who had received 16 cycles of chemotherapy had intrahepatic recurrence at 58 months after surgery. No recurrence was observed in 17 patients who had received 16 cycles of chemotherapy. CONCLUSION: Adjuvant hepatic arterial chemotherapy may be feasible to improve the survival of patients after resection of solitary HCC associated with HBV cirrhosis. BACKGROUND: Although resection is the major treatment for patients with hepatocellular carcinoma ( HCC), the high intrahepatic recurrence remains a cardinal cause of death. This study was undertaken to evaluate the effect of hepatic arterial infusion chemotherapy on the survival and recurrence of HCC patients with hepatitis B virus ( HBV) cirrhosis after resection. METHODS: Twenty-eight patients who had undergone placement of a hepatic arterial pump at the time of liver wedge resection for HCC from 1998 through 2004 were reviewed retrospectively. These patients aged 23-71 years had HBV cirrhosis (Child-Pugh class A or B). They were given floxuridine(FUDR) (250 mg), doxorubicin (10 mg) and mitomycin C (4 mg) alternatively every 2 or 3 days through arterial pumps for 8 cycles each year in the first two years after resection. Meanwhile, traditional Chinese herbal medicine was prescribed to the patients. When the leucocyte count was as low as 3 x 109/L or asparate aminotransferase (AST) level was significantly increased, the regimen of chemotherapy was delayed for the normalization of leucocyte count and AST level (below 80 U/L). RESULTS: Of the 28 patients, 23 received 8 or 16 cycles of the set regimen of chemotherapy. These patients are alive with no evidence of recurrence. Among them, 5,7, and 11 patients are alive beyond 5 years, 3 years, and 1 year respectively. In the remaining 5 patients, 3 who had had a HCC 10 cm or more in diameter showed tumor recurrence within 1 year, in whom, 8 cycles of chemotherapy were not completed because of their low leucocyte count (<3 × 109/L) and poor liver function. One patient who had received 8 cycles of chemotherapy demonstrated recurrence at 16 months after resection. One patient who had received 16 cycles of chemotherapy had intrahepatic recurrence at 58 months after surgery. No recurrence was observed in 17 patients who had received 16 cycles of chemotherapy. CONCLUSION: Adjuvant hepatic arterial chemotherapy may be feasible to improve the survival of patients after resection of solitary HCC associated with HBV cirrhosis.
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2006年第2期224-227,共4页 国际肝胆胰疾病杂志(英文版)
关键词 carcinoma hepatocellular hepatitis B virus cirrhosis RESECTION CHEMOTHERAPY carcinoma, hepatocellular hepatitis B virus cirrhosis resection chemotherapy
  • 相关文献

参考文献18

  • 1Takayama T,Sekine T,Makuuchi M,Yamasaki S,Kosuge T,Yamamoto J, et al.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomized trial. The Lancet . 2000
  • 2Cha CH,Ruo L,Fong Y,Jarnagin WR,Shia J,Blumgart LH, et al.Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Annals of Surgery . 2003
  • 3Sutcliffe R,Maguire D,Portmann B,Rela M,Heaton N.Selection of patients with hepatocellular carcinoma for liver transplantation. British Journal of Surgery . 2006
  • 4Cheon JH,Park JW,Park KW,Kim YI,Kim SH,Lee WJ, et al.The clinical report of 1078 cases of hepatocellular carcinomas:Natiomas:National Cancer Center experience. Korean Journal of Hepatology . 2004
  • 5Ercolani G,Grazi GL,Ravaioli M,Gaudio MD,Gardini A,Cescon M, et al.Liver resection for hepatocellular carcinoma on cirrhosis. Annals of Surgery . 2003
  • 6Adachi E,Maeda T,Matsumata T,Shirabe K,Kinukawa N,Sugimachi K, et al.Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology . 1995
  • 7Park JW,Park KW,Cho SH,Park HS,Less WJ,Lee do H, et al.Risk of hepatitis B exacerbation is low after tran-scatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma:report of a prospective study. The American journal of Gastroenterology . 2005
  • 8P oon RT,Fan ST,Lo CM,Ng IO,Liu CL,Lam CM, et al.Improving survival results after resection of hepatocellularcarcinoma: a prospective study of 377 patients over 10 years. Annals of Surgery . 2001
  • 9Gragi GL,Ercolani G,Pierangeli F,et al.Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Annals of Surgery . 2001
  • 10Lang BH,Poon RT,Fan ST,Wong J.Perioperative and long-term outcome of major hepatic resection for small solitary hepatocellular carcinoma in patients with cirrhosis. Archives of Surgery . 2003

共引文献7

同被引文献23

引证文献4

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部